BioNTech's chief executive Ugur Sahin told reporters Tuesday it is "highly likely" his company's COVID-19 vaccine, which was developed alongside Pfizer and has been rolled out in several countries including the United States, will hold up against the new coronavirus variant that was first identified in the United Kingdom.
Scientists have many questions about the variant, which appears to be more transmissible, including how it affects vaccine efficacy. Per Reuters, Sahin said he'll need another two weeks of study and data collection to determine whether the Pfizer-BioNTech shot will remain effective, but he is confident the mutations won't be enough to evade the immune response it induces. "The vaccine contains more than 1,270, and only nine of them are changed (in the mutant virus)," Sahin said. "That means 99 percent of the protein is still the same."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Today's political cartoons - February 22, 2025Cartoons Saturday's cartoons - bricking it, I can buy myself flowers, and more
-
5 exclusive cartoons about Trump and Putin negotiating peaceCartoons Artists take on alternative timelines, missing participants, and more
-
The AI arms raceTalking Point The fixation on AI-powered economic growth risks drowning out concerns around the technology which have yet to be resolved
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
